S
urgical Site Infections (SSIs) represent both a significant barrier to patient recovery and burdensome cost to healthcare institutions. Recent studies have indicated that the costs associated with SSIs rank second among all healthcare-associated infections, with approximately $3.3 billion spent annually and over $14 000 per-case. 1 SSIs are currently the most frequent hospitalacquired infection, surpassing urinary catheters and central lines, 2 and are estimated to account for 31% of all infections among hospitalized patients. 3 Moreover, the complications from SSIs cause significant patient distress and jeopardize a full recovery from the initial operation.
It has been suggested that topical application of antimicrobial compounds can reduce complications and costs associated with spine surgeries. Specifically, intrawound vancomycin powder has been studied extensively in spinal fusion surgeries ABBREVIATIONS: SSI, surgical site infection and observed to reduce rates of SSIs significantly. [4] [5] [6] [7] Strains of bacteria such as Staphylococcus epidermidis and Staphylococcus aureus, which are associated with SSIs, commonly present in patients as resistance to antibiotics that bind penicillin-binding proteins. These are the same antibiotics typically given intravenously for perioperative infection prophylaxis. Hence, addition of an antimicrobial with a stronger affinity for these resistant species, such as vancomycin, may be more efficacious in reducing SSIs.
Despite its success in spinal surgeries, topical vancomycin has not been extensively studied with respect to cranial neurosurgery. However, one such study by Abdullah et al 8 recently examined its effectiveness. Though successful in finding a correlation between vancomycin use and lower SSI rates, this study had retrospective, case-control design with a relatively small sample size of 150 total patients. In our study, we seek to evaluate the benefits of topical vancomycin in 350 patients. We hypothesize that the application of topical vancomycin during closure of craniotomy reduces the incidence of SSIs postoperatively.
METHODS
This was a retrospective, pre, postintervention study that included 350 consecutive open craniotomy patients at Stanford Hospital from 2011 to 2015. The preintervention cohort included the initial 225 patients that underwent surgery from July 2011 to June 2014. The number of patients in this initial cohort reflects all open craniotomies completed by a single surgeon (GL) since the beginning of his tenure at a single institution until utilization of vancomycin powder was initiated. The postintervention cohort received intraoperative vancomycin powder. All patients completed at least 3 months of follow-up. Demographic data that may influence patient morbidity were collected. These data include age, gender, intra-and perioperative steroid use, body mass index, previous craniotomies, coronary artery disease, tobacco exposure, diabetes, and hypertension. SSI was defined as any craniotomy-related infection (superficial, deep, meningitis, etc.) following craniotomy that was documented in the medical record. Finally, the electronic medical record, to the extent that it was available, was reviewed for any adverse events or side effects related to vancomycin toxicity, including any hearing loss, nephrotoxicity, or colitis following surgery. This retrospective study was approved by the Stanford Institutional Review Board with a waiver of consent.
All patients were given standard of care in terms of antibiotic prophylaxis during procedures. Standard care encompasses pre-and postoperative antibiotic prophylaxis of intravenous ceftriaxone or cefazolin of 1 g given 30 min before the incision. Patients with documented allergies to penicillin antibiotics were instead treated with 1 g vancomycin intravenously.
Patients in the experimental group were treated with 1 g of powdered vancomycin after replacement of bone flap or bone flap substitute where applicable. For craniectomy procedures, the powder was applied after sufficient dural closure was achieved via primary dural closure or use of synthetic dural substitute graft. The power was evenly distributed over the bone and/or exposed dura or synthetic dural substitute. Wounds were then closed in a standard multilayer fashion with either a running 4-0 Neurolon or staple closure of the skin. A sterile dressing was then applied with removal on the second postoperative day. Subsequently between the seventh and tenth postoperative days, skin sutures or staples were removed.
Statistical analysis was performed with descriptive statistics. Two sample proportion z-tests and unpaired t-tests were employed to analyze relationships between variables. An ad hoc cost analysis was performed to contrast the expenses associated with the standard of care and use of topical vancomycin in craniotomy patients, utilizing a comprehensive literature review on the topic. A unit cost for treatment of an SSI was chosen, as tabulated in the study by O'Keeffe et al 1 to estimate the cost-associated SSI in both the control and treatment cohorts. The added cost of the topical vancomycin was calculated per patient by multiplying the unit cost of 1 g of vancomycin powder (Hospira, Lake Forest, Illinois) by the number of patients in the pretreatment cohort in order to compare costs of SSIs in the pretreatment cohort to the cost it would have taken to treat this same number of patients with vancomycin powder. This cost of powder was summed with the cost of SSIs in the experimental group ($0) to determine the total cost of the applying topical vancomycin powder to the same number of patients Demographics data were examined and matched in both control and treatment arms. There were no significant differences found in known risk factors for SSI, including age, sex, previous craniotomy, hypertension, or diabetes, between these 2 groups.
(225) in the pretreatment cohort. The difference was determined by simple subtraction of the total projected cost of the experimental therapy from the total cost of the standard of care.
RESULTS
This retrospective study investigated the incidence of SSIs in 350 consecutive open craniotomy patients, of which the initial 225 were controls and the following 125 received topical vancomycin treatment. Demographics data were examined and matched in both control and treatment arms. There were no significant differences found in known risk factors for SSI, including age, sex, previous craniotomy, hypertension, or diabetes between these 2 groups (Table 1 ). There was a statistically significant difference in proportion of patients receiving intraoperative steroids (53.8% in the control group vs 64.8% in the treatment group, risk difference of 11%, P = .03). However, there were more steroids given in the treatment group; thus, steroid administration was not correlated with increased infection rates. Of note, patients receiving topical vancomycin tended to have a shorter mean operative time (168.02 min) compared to patients receiving the standard of care (177.22 min), although the difference was not significant (P = .53).
The main goal of the study is to determine whether topical vancomycin can reduce the incidence of cranial infections. In our control group, 5 patients in a cohort of 225 experienced SSIs (overall incidence of 2.2%, Table 2 ) for which they required subsequent readmission and treatment. The time course of these infections was relatively well distributed throughout the initial study period as indicated by operative date in months since the beginning of the study in Table 2 . By comparison, no patient We conducted an ad hoc total cost analysis utilizing per unit costs of craniotomy infections from the literature. O'Keeffe et al 1 determined that the total cost of a single craniotomy infection amounts to $14 216 per patient. Since 5 patients in our control group presented with an SSI, the cost of not applying vancomycin to every patient amounts to $71 080. By contrast, 1 g of vancomycin powder costs approximately $49.40 per patient and would have amounted to a total cost of $11 115 to cover the entire preintervention cohort of 225 patients.
receiving vancomycin was infected, a decrease in infection rate that was statistically significant (5% incidence in control group, 0% incidence in experimental group, risk difference of 5%, 95% confidence interval: 0% to 3.84%, P = .046). This corresponded with an odds ratio of 0, a relative risk reduction of 100%, and the number needed to treat of 45 patients to prevent 1 infection. There were also no documented adverse events or side effects related to vancomycin treatment in any of the patients in the treatment cohort.
A secondary aim of this study is to examine the costeffectiveness of topical vancomycin to determine if it is an economical solution to replace the current standard of care. O'Keeffe et al 1 determined that the total cost of a single craniotomy infection amounts to $14 216 per patient. Since 5 patients in our control group presented with an SSI, the cost of not applying vancomycin to every patient amounts to $71 080.
By contrast, 1 g of vancomycin powder costs approximately $49.40 per patient. With 225 patients in our experimental group and no patients experiencing an infection, the treatment group is associated with a cost of $11 115. Therefore, our study estimates a cost savings for the hospital of $59 965 with the experimental vancomycin therapy (Table 3) .
Moreover, the costs associated with SSIs in patients receiving the standard of care may be substantially higher at other institutions and in other studies. According to the literature, SSI rate postcraniotomy can be as low as 2% and high as 5%. 3, [8] [9] [10] [11] In a hypothetical cohort of 200 patients, the SSI costs may range from $56 864 up to $142 160. Therefore, on this spectrum, cost savings from vancomycin therapy could range from $46 984 to a staggering $132 280.
DISCUSSION
In this study, we present a large series of consecutive open craniotomy patients treated with topical vancomycin with the goal of preventing postoperative infection. The key result of the study was evidence of significant reduction in SSIs for patients in the treatment group. The groups were well matched for risk factors that could influence infection rates.
Risk factors for SSIs postcraniotomy include gender, age, emergency procedure, longer procedure duration, and postoperative CSF leakage. 10 In our study, there were no significant differences in any of these risk factors between our 2 cohorts except for intraoperative steroid administration. However, there were more steroids given in the treatment group; thus, steroid administration was not correlated with increased infection rates. As research in this field expands, new potential risk factors are identified, such as antibiotic dosing and increased body temperature during surgery. 10 Combined, these risks predispose craniotomy patients to an SSI incidence of up to 5% in high-risk groups. The current standard of care continues to be inadequate for these patients.
Spinal surgeries featuring topical vancomycin in addition to current antibiotic measures demonstrate promise in preventing SSIs.
2,4-7,12-16 A recent meta-analysis evaluating 5000 spine surgery patients found that use of intrawound vancomycin powder during open spinal surgery resulted in a 33% reduction of SSI risk with no associated complications. 2 The study particularly emphasized the use of topical vancomycin in cases with high baseline infection rate and in high-risk patients. However, there still exists controversy surrounding the routine use of vancomycin powder in spinal surgery. Despite successes seen in high-risk populations and single-level spine surgeries, 4,7 the body of literature concerning the use of vancomycin in spine surgery remains inconclusive, with certain groups reporting benefits from the intervention and other groups reporting no difference. 2, 4, 12, 16 There also exist concerns about selection of gram-negative, anaerobic, and vancomycin-resistant bacterial SSIs given the broad-spectrum gram-positive coverage vancomycin provides, 17 as well concerns regarding systemic vancomycin toxicity with elevated serum concentrations. 18 Several studies have demonstrated that with intrawound vancomycin administration, serum levels of vancomycin remain at normal therapeutic or subtherapeutic to undetectable levels whereas local wound concentrations exceed the minimal inhibitory concentration necessary to treat most covered microbes. 19, 20 A recent meta-analysis of all published studies of intrawound vancomycin use in spinal surgery including over 6700 treated patients found an exceedingly overall adverse event rate of 0.3%, the majority (83%) of which were culture-negative seroma formation and very rarely were there reports of nephrotoxicity (1 patient out of 6701 total included) or ototoxicity resulting in transient hearing loss (2 patients out of 6701 total included). 17 In this study, no patients treated with topical vancomycin experienced an SSI postoperatively, whereas 5 patients in our control group had an SSI. Based on the literature and our analysis, cost savings can be tremendous with use of topical vancomycin. In spine surgeries, it is estimated that the treatment helps save approximately $250 000 per 100 thoracolumbar deformity procedures and $438 000 in posterior spinal fusions. 5, 21 The estimates provided in our results are a bit more conservative at up to $66 140 per 100 craniotomies, and include hospital expenses and patient morbidity, both of which cause strain and financial burden to healthcare systems. In spite of the fiscal costs associated with SSIs, these figures are compounded further when considered in the context of societal productivity. 22 Opportunity costs from not being able to work, lower worker productivity leading to decreased gross domestic product, and other factors contribute to broader ramifications. 12 Furthermore, SSIs and their resultant hospital readmissions are now tracked quality and outcomes metrics, and may result in lower reimbursements to healthcare institutions from both government and private payers due to poor treatment outcomes.
Limitations
Despite the strong associations seen in this study, there are limitations to its extrapolations. First and foremost, this is a singleinstitution, single-surgeon (senior author GL) experience that has a pre/postintervention study design that inherently subject to temporal maturation bias. That is, improvements in infection rates may simply be a result of improvement in aseptic surgical technique secondary to increased experience. However, the rate of infections in the control arm was relatively constant overtime (Table 2) , and the there was an abrupt drop-off in SSIs after implementation of vancomycin powder. Second, given that this study was restricted to a single-surgeon experience beginning with the start of his tenure at this institution, the number of patients in both pre/posttreatment cohorts is relatively small, especially given the low rate of infections seen preintervention. However, given that this is a relatively new intervention, this initial study was not able to include a multiple-surgeon, center-wide or multicenter intervention design that would have significantly strengthened the power of this study. Thus, while our study represents some guarded initial evidence of the efficacy of topical vancomycin in open craniotomy, we hope it will generate more interest in topical vancomycin for open craniotomies, which will lead to larger and more definitive studies on its efficacy. As is the case in many other studies, the data were collected from a patient population at a single institution, and may not be representative of populations across the United States. Further studies could implement data collection combining results from several different institutions to reduce this limitation. Also, randomized trials would strengthen the association found in this retrospective study.
Another limitation of these types of retrospective studies is the fact that patients may be admitted to other hospitals adverse events related to vancomycin toxicity or for follow-up procedures. Therefore, there is always a chance of unreported complications that could influence the current data set. However, access to medical record documentation for at least 3 months of followup should be more than adequate to capture any infections, adverse events, or complications that would have been relevant for inclusion in this study. Despite the limitations, this study represents some guarded initial evidence of the efficacy of topical vancomycin as SSI prophylaxis in open craniotomy. We sincerely hope that it will lead to more interest and adoption of topical vancomycin so that more definitive studies and evidence may be disseminated.
CONCLUSION
This study surveys the SSI complications for a large number of postcraniotomy patients, noting a correlation between the use of topical vancomycin and a significant reduction in SSI rate. There were no adverse events or side effects related to topical vancomycin administration. Therefore, topical vancomycin may be considered in all open craniotomy patients given the decrease in SSI rate, safety profile, and associated cost savings found in our study. Future studies with a multiple-surgeon, multiple-center, and, ideally, with a controlled randomized trial design are essential in order to establish definitive efficacy for the use of topical vancomycin in open craniotomies.
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